Clinical Outcomes of Lenvatinib-Pembrolizumab in a High-Risk, Dual ICI-Refractory Melanoma Cohort.

In this high-risk, dual immune checkpoint inhibitors-refractory cohort, lenvatinib plus pembrolizumab showed manageable toxicity and clinical outcomes broadly consistent with previous reports.

Although limited by the small sample size and retrospective design, these findings support the feasibility of this regimen in routine clinical practice and warrant further prospective evaluation.